Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Master Protocol for Three Independent, Seamlessly Enrolling, Double-blind, Placebo-controlled Efficacy and Safety Studies of ACP-204 in Adults With Alzheimer's Disease Psychosis

NCT06159673 is registered in ClinicalTrials.gov with ACADIA Pharmaceuticals Inc. as lead sponsor.

NCT NCT06159673
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06159673 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Master Protocol for Three Independent, Seamlessly Enrolling, Double-blind, Placebo-controlled Efficacy and Safety Studies of ACP-204 in Adults With Alzheimer's Disease Psychosis
Lead sponsor
ACADIA Pharmaceuticals Inc.
Phase
Phase 2/3
Overall status
Recruiting
Start date
November 14, 2023
Completion date
February 29, 2028
Enrollment
1,074 (estimated)
Sites
152

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease psychosis